Kidney transplant patients: which drug prevents rejection better?
NCT ID NCT05193565
First seen Feb 25, 2026 · Last updated May 24, 2026 · Updated 12 times
Summary
This study looks at kidney transplant patients who are at least one year post-transplant and currently taking a combination of two immunosuppressant drugs. Researchers want to see if switching to one of two alternative drugs (RaparoBell® or My-Rept®) is safer and more effective at preventing organ rejection, graft loss, or death. The study involves 206 participants and will track outcomes like biopsy-confirmed rejection and survival of the transplanted kidney.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.